--- title: "Hong Kong stock movement: CLOUDBREAK-B plummets 20.05%, with judicial preservation and pressure from unlocked shares severely impacting stock price" type: "News" locale: "en" url: "https://longbridge.com/en/news/271881135.md" description: "CLOUDBREAK-B fell 20.05%; Kelun-B dropped 1.82%, with a transaction volume reaching HKD 1.101 billion; Innovent Biologics had a transaction volume of HKD 874 million; 3SBio fell 0.36%, with a transaction volume reaching HKD 498 million; BeiGene rose 0.50%, with a market value reaching HKD 307.8 billion" datetime: "2026-01-08T05:36:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/271881135.md) - [en](https://longbridge.com/en/news/271881135.md) - [zh-HK](https://longbridge.com/zh-HK/news/271881135.md) --- # Hong Kong stock movement: CLOUDBREAK-B plummets 20.05%, with judicial preservation and pressure from unlocked shares severely impacting stock price **Hong Kong Stock Movement** CLOUDBREAK-B fell 20.05%. Based on recent news, 1. On January 6, CLOUDBREAK in Guangzhou received a court notice that its bank accounts were subject to judicial preservation, involving an amount of approximately RMB 2.55 million. Although the company stated that this procedure did not have a significant adverse impact on its business, the market reacted strongly, leading to a sharp decline in stock price. 2. On January 5, the lock-up period for cornerstone investor FuCe Holdings Limited in CLOUDBREAK ended, with approximately 17.72 million shares being unlocked. Although FuCe Holdings voluntarily extended the lock-up period, the market still faced selling pressure from the unlocked shares, further suppressing the stock price. 3. On January 6, CLOUDBREAK announced that its core product CBT-009's new drug clinical trial application had been submitted to the China National Medical Products Administration. While this is a positive development, it failed to offset the impact of the aforementioned negative news on the stock price. The market reacted strongly to the judicial preservation and unlocked shares, leading to a significant drop in stock price. **Stocks with High Trading Volume in the Industry** Kelong Botai Bio-B fell 1.82%. Based on recent key news: 1. On January 8, Kelong Botai Bio-B recorded large transactions, with the transaction price down 7.22% compared to the previous close, affecting market confidence and leading to a decline in stock price. Source: Economic Information Daily 2. On January 7, the company terminated its subscription for RMB 980 million in structured deposits from Bank of China, adjusting its wealth management strategy, which did not have a significant impact on its financial status. Source: Zhitong Finance 3. On January 5, Kelong Botai Bio-B's core product received breakthrough therapy designation from the China National Medical Products Administration, boosting market confidence in the company's R&D capabilities. Source: Economic Information Daily, the pharmaceutical sector's innovative drug development accelerates, attracting market attention. Innovent Biologics had a trading volume of HKD 874 million. Based on recent key news: 1. On January 5, Innovent Biologics' stock price surged 6%, mainly benefiting from capital inflow after the mainland stock market reopened. Northbound funds net bought HKD 18.7 billion, driving up pharmaceutical stocks. Source: Now News Channel 2. On January 6, Innovent Biologics' GLP-1 weight-loss drug MaShiduTide performed outstandingly in market competition. Nomura Securities analysts pointed out that its differentiated mechanism and high pricing made it stand out, maintaining a "Buy" rating. Source: Jinshi Data 3. On January 6, Daiwa Securities raised Innovent Biologics' target price to HKD 112, emphasizing its strong performance in the biopharmaceutical sector. Source: Zhitong Finance, the pharmaceutical industry shows growth differentiation, driven by chronic diseases. 3SBio fell 0.36%. Based on recent key news: 1. On January 6, 3SBio recorded large cross-trade transactions, with a transaction amount exceeding HKD 60.71 million, and the stock price slightly fell to HKD 25.96. This transaction indicates active market interest in the stock; despite the slight decline in stock price, there was a net active buy of HKD 33.17 million, indicating that investors remain optimistic about its future performance. Source: Economic Information Daily 2. On January 8, CMB International released a weekly report on the pharmaceutical industry, pointing out that the Hong Kong stock market's pharmaceutical sector performed well, with BeiGene recommended as a focus in the innovative drug field. The report believes that the pharmaceutical sector will stabilize and improve by 2026, and BeiGene's valuation has not yet fully reflected the value of its core blockbuster products, which may become a market catalyst. Source: Jinwu Financial News 3. On January 5, Guoyuan Securities maintained a buy rating for BeiGene, with a target price of HKD 32.76. The analyst consensus is a strong buy, with an average target price of HKD 42.69, indicating positive market expectations for the stock. Source: Guoyuan Securities (Hong Kong) Analyst Report on the strong performance of the pharmaceutical sector, focusing on innovative drugs. **Stocks ranked at the top of the industry by market capitalization** BeiGene rose by 0.50%. Based on recent key news: 1. On January 6, BeiGene announced that its new drug Brukinsa® received conditional approval from the National Medical Products Administration for the treatment of patients with chronic lymphocytic leukemia and mantle cell lymphoma. This approval brings new market opportunities for the company, driving up its stock price. Source: Jinshi Data 2. On January 7, BeiGene granted a total of 53,300 restricted stock units of American Depositary Shares to 155 grantees, accounting for approximately 0.04% of the company's total issued shares. This move may enhance employee incentives and support the stock price. Source: Zhito Finance 3. On January 8, CMB International released a weekly report on the pharmaceutical industry, pointing out that the Hong Kong stock market's pharmaceutical sector performed well, with BeiGene recommended as a target rich in innovative drug catalysts, further driving up its stock price. Source: Jinwu Financial News The Hong Kong stock market's pharmaceutical sector performed well, with significant capital inflow ### Related Stocks - [02592.HK](https://longbridge.com/en/quote/02592.HK.md) ## Related News & Research - [US probing if China firms cut output of containers before pandemic, says CBS](https://longbridge.com/en/news/286944311.md) - [Coffee Prices Rebound on Technical Short-Covering](https://longbridge.com/en/news/286941721.md) - [Gen Z's AI backlash is getting louder](https://longbridge.com/en/news/286922566.md) - [DJI’s e-bike division tries to defend why its motors are so insanely powerful](https://longbridge.com/en/news/286894898.md) - [Dunkin' To Give Away 1 Mln Free Coffees For A Day](https://longbridge.com/en/news/286964019.md)